JPRN-jRCT2080221679未知3 期
Efficacy and safety of vildagliptin as add-on therapy to metformin in patients with type 2 diabetes
ovartis Pharma K.K.0 个研究点目标入组 136 人开始时间: 2011年12月21日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 136
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Patients with type 2 diabetes inadequately controlled with diet, exercise and oral anti-diabetic therapy
- •- HbA1c in the range of 7.0-10.0%
- •- Body mass index in the range 20-35 kg/m2
排除标准
- •- Type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes
- •- Significant heart diseases
研究者
相似试验
已完成
不适用
To compare the effect of pioglitazone vs vildagliptin in type 2 diabetes mellitus patients not responding to combination of metformin and sulfonylureas.CTRI/2013/04/003582investigator initiated trial50
已完成
不适用
Efficacy and Safety of Vildagliptin in Type 2 DiabetesCTRI/2022/01/039112Cipla Limited1,691
招募中
不适用
Comparison of efficacy and safety of Vildagliptin and Teneligliptin in patients with Type 2 Diabetes MellitusCTRI/2017/02/007766jawaharlal nehru medical college and hospital160
招募中
4 期
An study to assess the safety and efficacy of vildagliptin vs voglibose in management of post-prandial blood sugar in patients with T2DMCTRI/2024/08/072355Dr Mahima V
未知
3 期
To assess the efficacy and safety of vildagliptin as add-on therapy to sulfonylurea in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapyType 2 DiabetesJPRN-jRCT2080220244ovartis Pharma K.K.200